BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38492130)

  • 1. Circulating Bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome.
    Yang Y; Gu M; Wang W; Li S; Lu J; Sun Q; Hu M; Zhong L
    Clin Exp Med; 2024 Mar; 24(1):55. PubMed ID: 38492130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMP9 promotes methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in non-obese mice by enhancing NF-κB dependent macrophage polarization.
    Jiang Q; Li Q; Liu B; Li G; Riedemann G; Gaitantzi H; Breitkopf-Heinlein K; Zeng A; Ding H; Xu K
    Int Immunopharmacol; 2021 Jul; 96():107591. PubMed ID: 33812253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of
    Toda-Oti KS; Stefano JT; Cavaleiro AM; Carrilho FJ; Correa-Gianella ML; Oliveira CPMS
    Metab Syndr Relat Disord; 2022 Mar; 20(2):114-123. PubMed ID: 35020496
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease.
    Wu X; Cheung CKY; Ye D; Chakrabarti S; Mahajan H; Yan S; Song E; Yang W; Lee CH; Lam KSL; Wang C; Xu A
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3230-e3240. PubMed ID: 35532410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study.
    Kim BJ; Kim HS; Kang JG; Kim BS; Kang JH
    J Clin Lipidol; 2016; 10(6):1423-1430.e1. PubMed ID: 27919360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression.
    Yang Z; Li P; Shang Q; Wang Y; He J; Ge S; Jia R; Fan X
    Sci Adv; 2020 Nov; 6(48):. PubMed ID: 33246954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease Severity Is Related to Plasma Pro-Oxidative Biomarkers Rather Than Liver Tissue-Measured Nitrogen Metabolism Biomarkers in Population with Obesity and Metabolic Syndrome.
    Suárez-Cuenca JA; Domínguez-Pérez GA; Hernández-Muñóz RE; Hernández-Patricio A; Vera-Gómez E; Gutiérrez-Buendía JA; Salamanca-García M; Montoya-Ramírez J; Gaytán-Fuentes OF; Aranda-Rodríguez C; Rojas-Noverón AR; García S; Mondragón-Terán P
    Metab Syndr Relat Disord; 2023 Mar; 21(2):115-121. PubMed ID: 36787445
    [No Abstract]   [Full Text] [Related]  

  • 10. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
    Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
    Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
    World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis.
    Eguchi A; Iwasa M; Yamada M; Tamai Y; Shigefuku R; Hasegawa H; Hirokawa Y; Hayashi A; Okuno K; Matsushita Y; Nakatsuka T; Enooku K; Sakaguchi K; Kobayashi Y; Yamaguchi T; Watanabe M; Takei Y; Nakagawa H
    Hepatol Commun; 2022 Aug; 6(8):1987-1999. PubMed ID: 35485207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into BMP9 signaling in liver diseases.
    Jiang QQ; Liu BB; Xu KS
    Mol Cell Biochem; 2021 Oct; 476(10):3591-3600. PubMed ID: 34019202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity.
    Peng L; Wu S; Zhou N; Zhu S; Liu Q; Li X
    BMC Pediatr; 2021 Mar; 21(1):122. PubMed ID: 33711964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
    Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
    Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice.
    Sun QJ; Cai LY; Jian J; Cui YL; Huang CK; Liu SQ; Lu JL; Wang W; Zeng X; Zhong L
    Front Pharmacol; 2020; 11():605967. PubMed ID: 33603666
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.